Form 4: Disc Medicine Director Granted Stock Options

Disc Medicine Director Georges Gemayel was granted 1,000 stock options with an exercise price of $60.34, vesting based on service and future events.

Summary

• Georges Gemayel, a Director of Disc Medicine, Inc. (IRON), was granted 1,000 stock options.
• The transaction date for this grant was September 16, 2025.
• Each stock option has an exercise price of $60.34.
• The options will vest upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (September 16, 2026), contingent on Mr. Gemayel's continued service.
• The expiration date for these stock options is September 15, 2035.
• Following this transaction, Mr. Gemayel beneficially owns 1,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event for a director, which aligns their interests with shareholders. It does not indicate any significant operational or financial changes, but rather standard corporate governance practice.

Positives

• The grant of stock options aligns the Director's financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The vesting of these stock options is tied to future events, specifically the Company's 2026 annual meeting or the one-year anniversary of the grant date, and the Director's continued service, indicating a forward-looking incentive for long-term commitment.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a form of equity compensation to attract, retain, and incentivize key leadership by linking their financial success to the company's performance.

Comparison to Industry Standards

• Equity compensation for directors, often in the form of stock options or restricted stock units, is a standard component of executive and board remuneration across publicly traded companies, particularly in growth-oriented sectors like biotech.
• The vesting schedule, tied to continued service and a future corporate event, is typical for aligning director interests with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.

Next Steps

• The stock options will vest upon the earlier of the Company's 2026 annual meeting or September 16, 2026, subject to continued service.
• Georges Gemayel may exercise the vested options at the specified exercise price before the expiration date of September 15, 2035.

Key Dates

Keywords

Disc Medicine, IRON, stock option, director compensation, insider transaction, equity grant, Form 4